PMAM
EW icon

Picton Mahoney Asset Management’s Edwards Lifesciences EW Stock Holding History

Picton Mahoney Asset Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-442,425
Closed -$16.1M – 190
2017
Q3 		$16.1M Buy
+442,425
New +$16.9M 1.21% 28

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Picton Mahoney Asset Management's EW Position: Q2 2025 in Review

Picton Mahoney Asset Management sold out of Edwards Lifesciences (EW) in Q2 2025, closing a stake of 63 shares — an estimated $4K sold.

Picton Mahoney Asset Management first reported a position in EW in Q4 2015 and held it in 15 quarters. The position peaked at $51.8M in Q3 2016. 1,260 funds tracked by Wall St. Rank hold EW as of Q2 2025.

  • Picton Mahoney Asset Management reported no remaining Edwards Lifesciences position as of Q2 2025 after selling out during the quarter.
  • Picton Mahoney Asset Management sold 63 Edwards Lifesciences shares in Q2 2025, an estimated $4K.
  • Picton Mahoney Asset Management first reported a position in Edwards Lifesciences in Q4 2015 and held it in 15 quarters.
  • Picton Mahoney Asset Management's Edwards Lifesciences position peaked at $51.8M in Q3 2016.
  • 1,260 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2025.

Based on Picton Mahoney Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.